Publications by authors named "D Nikolopoulos"
Molecular basis for the disease-modifying effects of belimumab in systemic lupus erythematosus and molecular predictors of early response: blood transcriptome analysis implicates the innate immunity and DNA damage response pathways.
Ann Rheum Dis
November 2024
Article Synopsis
- The study investigates how belimumab, a drug for systemic lupus erythematosus (SLE), affects blood gene expression and whether early treatment response can be predicted through blood tests.
- RNA sequencing was conducted on blood samples from 45 active SLE patients before and after 6 months of treatment, revealing significant changes in gene expression related to immune cell activity and disease severity.
- Results indicate that belimumab reduces specific immune pathways and may reverse disease markers, with a model predicting treatment response based on 50 genes showcasing 84% accuracy.
Penetrating trauma of the femur poses significant life-threatening risks due to potential complications, particularly involving the femoral structures such as the femoral artery, femoral vein, and femoral nerve. These injuries can lead to severe outcomes, especially when accompanied by soft tissue damage. Effective management requires a thorough understanding of the injury's nature, including the extent of soft tissue involvement and associated complications.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to understand how systemic lupus erythematosus (SLE) progresses after starting therapy, focusing on different patient responses and outcomes.
- Researchers analyzed data from 2868 patients across four clinical trials, identifying four distinct disease evolution characteristics based on both clinical measures and patient-reported outcomes.
- The findings suggest that categorizing patients into these trajectories could help personalize treatments and improve future clinical study designs, as no single factor can predict how SLE will progress.
Systemic lupus erythematosus is the prototype multisystem autoimmune disorder characterised by a broad spectrum of organ involvement and a multitude of laboratory abnormalities. Clinical heterogeneity, unpredictable course and lack of pathognomonic clinical and serological features pose a considerable challenge in the diagnosis of SLE. The latter remains largely clinical, typically accompanied however by features of serologic autoimmunity, which are characteristic for the disease.
View Article and Find Full Text PDFSystemic lupus erythematosus (SLE) is a chronic autoimmune disease that is characterised by a wide range of symptoms and a risk for irreversible organ damage, leading to increased morbidity and mortality. To improve long-term outcomes, innovative therapeutic goals have been explored, including attainment and maintenance of remission or low disease activity, with minimal use of glucocorticoids. Other goals encompass early diagnosis, potent yet less toxic therapies, appropriate glucocorticoid tapering, and better quality of life for the patients.
View Article and Find Full Text PDF